GILD
Price
$157.19
Change
+$3.62 (+2.36%)
Updated
Oct 22 closing price
Capitalization
194.91B
7 days until earnings call
Intraday BUY SELL Signals
SNY
Price
$41.96
Change
+$0.99 (+2.42%)
Updated
Oct 22 closing price
Capitalization
100.54B
8 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GILD vs SNY

GILD vs SNY Comparison Chart in %
View a ticker or compare two or three
VS
GILD vs. SNY commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Buy and SNY is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GILD with price predictions
Oct 22, 2026

Momentum Indicator for GILD turns positive, indicating new upward trend

GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 55 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 34 of 55 cases over the following month. The odds of a continued upward trend are 62%.

Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 133 of 270 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 61 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 38%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.479) is normal, around the industry mean (-3.019). GILD's P/E Ratio (-60.226) is considerably lower than the industry average of (21.251). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).

The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for SNY with price predictions
Oct 22, 2026

SNY's RSI Oscillator ascending out of oversold territory

The RSI Indicator for SNY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 19 of the 27 cases the stock moved higher. This puts the odds of a move higher at 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 61 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 23 of 48 cases over the following month. The odds of a continued upward trend are 48%.

Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 156 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

SNY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SNY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.453) is normal, around the industry mean (-3.019). P/E Ratio (25.508) is within average values for comparable stocks, (21.251). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.189) is considerably higher than the industry average of (0.041). P/S Ratio (1.829) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

FUNDAMENTALS RATINGS
GILD vs SNY: Fundamental Ratings
GILD
SNY
OUTLOOK RATING
1..100
7414
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
77
Overvalued
PROFIT vs RISK RATING
1..100
987
SMR RATING
1..100
9681
PRICE GROWTH RATING
1..100
2069
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
3750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for SNY (77) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.

GILD's Profit vs Risk Rating (9) in the Biotechnology industry is significantly better than the same rating for SNY (87) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than SNY’s over the last 12 months.

SNY's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as GILD (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to GILD’s over the last 12 months.

GILD's Price Growth Rating (20) in the Biotechnology industry is somewhat better than the same rating for SNY (69) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.

SNY's P/E Growth Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (100) in the Biotechnology industry. This means that SNY’s stock grew significantly faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDSNY
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
38%
Bearish Trend 1 day ago
49%
Momentum
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
62%
MACD
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
48%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
44%
Bullish Trend 1 day ago
53%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
47%
Advances
ODDS (%)
Bullish Trend 8 days ago
64%
Bullish Trend 7 days ago
51%
Declines
ODDS (%)
Bearish Trend 4 days ago
47%
Bearish Trend 10 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
52%
Bearish Trend 1 day ago
57%
Aroon
ODDS (%)
Bullish Trend 1 day ago
49%
Bearish Trend 1 day ago
52%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (GILD: $157.19 vs. SNY: $40.97)
Brand notoriety: GILD: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 97% vs. SNY: 104%
Market capitalization -- GILD: $194.91B vs. SNY: $100.54B
GILD [@Pharmaceuticals: Major] is valued at $194.91B. SNY’s [@Pharmaceuticals: Major] market capitalization is $100.54B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.13T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $206.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 3 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).

  • GILD’s FA Score: 3 green, 2 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, GILD is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 4 bullish, 3 bearish.
  • SNY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GILD is a better buy in the short-term than SNY.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а -0.11% price change this week, while SNY (@Pharmaceuticals: Major) price change was +3.02% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.32%. For the same industry, the average monthly price growth was -5.34%, and the average quarterly price growth was +5.08%.

Reported Earning Dates

GILD is expected to report earnings on Oct 29, 2026.

SNY is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+0.32% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
GILD
Daily Signal:
Gain/Loss:
SNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
+2.42%
PFE - SNY
47%
Loosely correlated
+1.91%
JNJ - SNY
36%
Loosely correlated
+3.81%
MRK - SNY
35%
Loosely correlated
-1.76%
AMGN - SNY
35%
Loosely correlated
+2.04%
GILD - SNY
34%
Loosely correlated
+2.36%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JRVR4.010.14
+3.62%
James River Group Holdings Ltd
ACGL102.692.41
+2.40%
Arch Capital Group Ltd
PETZ1.300.03
+2.36%
TDH Holdings
BBDC8.340.09
+1.09%
Barings BDC
CAAP24.44-0.99
-3.89%
Corporacion America Airports SA